- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Polycythemia vera (PV)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Ruxolitinib – November 2019
Ruxolitinib: Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg; Jakavi®
Last updated
20 March 2020